<DOC>
	<DOC>NCT01933672</DOC>
	<brief_summary>Study B1621019 will assess efficacy and safety of two different dosing regimens of an investigational agent (PF-04937319) compared to an approved drug (sitagliptin) in patients with type 2 diabetes</brief_summary>
	<brief_title>Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Patients with type 2 diabetes, on background metformin therapy either alone or with 1 other oral antidiabetic agent (excluding Actos) Patients with cardiovascular event within 6months of screening Patients with diabetic complications Female subjects who are pregnant or planning to become pregnant Subjects with unstable medical conditions (eg, hypertension)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Phase 1b</keyword>
	<keyword>type 2 diabetes</keyword>
	<keyword>metformin background</keyword>
	<keyword>PF-04937319</keyword>
</DOC>